PMID- 12057850
OWN - NLM
STAT- MEDLINE
DCOM- 20030812
LR  - 20190826
IS  - 0165-2478 (Print)
IS  - 0165-2478 (Linking)
VI  - 83
IP  - 1
DP  - 2002 Aug 1
TI  - Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective 
      inducer of tumor-specific immunity in a peritoneal dissemination model.
PG  - 13-20
AB  - Dendritic cells (DCs) from cancer patients, as well as tumor-infiltrating DCs, 
      are reported to have suppressed immunostimulatory capacity. One of the major 
      problems in the clinical use of DCs for treating tumors is that the DCs must be 
      autologous ones obtained from patients. Compared with normal DCs (nDCs), 
      flow-cytometric analysis and allogeneic mixed lymphocyte reaction (MLR) have 
      revealed lower expression of the costimulatory molecules and suppressed 
      T-cell-stimulatory activity in DCs derived from tumor-bearing mice (tDCs) despite 
      of culture. We reported previously that the interleukin-12 
      (IL-12)-gene-transduced nDCs inhibited tumor growth due to induced tumor-specific 
      Th1 and cytotoxic T cells (CTLs) in a murine established subcutaneous tumor 
      model. In the present study, we examined whether tDCs could induce immune 
      responses against tumors after IL-12-gene transduction in an established 
      peritoneal dissemination model. The intraperitoneal injection of 
      IL-12-gene-transduced tDCs resulted in prolonged survival of some treated mice 
      (log-rank test; P=0.001) and tumor-specific Th1 and CTL activity. The injection 
      of IL-12-gene-transduced nDCs prolonged the survival of all treated mice 
      (P<0.0001) and elicited tumor-specific immunity, which were better than those of 
      IL-12-gene-transduced tDCs. Taken together, DC modification of IL-12-gene 
      transduction is an effective and promising approach for cancer therapy even when 
      immunosuppressive tDCs are employed.
FAU - Furumoto, Katsuyoshi
AU  - Furumoto K
AD  - Department of Surgery and Surgical Basic Science, Graduate School of Medicine, 
      Kyoto University, 54 Shogoin Kawara-cho, Sakyo-ku, Kyoto 606-8507, Japan. 
      furumoto@stanford.edu
FAU - Mori, Akira
AU  - Mori A
FAU - Yamasaki, Seiji
AU  - Yamasaki S
FAU - Inoue, Naoya
AU  - Inoue N
FAU - Yang, Weige
AU  - Yang W
FAU - Nakau, Masayuki
AU  - Nakau M
FAU - Yasuda, Seiichi
AU  - Yasuda S
FAU - Arii, Shigeki
AU  - Arii S
FAU - Imamura, Masayuki
AU  - Imamura M
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 187348-17-0 (Interleukin-12)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adenocarcinoma/immunology/secondary/*therapy
MH  - Animals
MH  - Dendritic Cells/*immunology/transplantation
MH  - *Genetic Therapy
MH  - Interferon-gamma/metabolism
MH  - Interleukin-12/*genetics/immunology
MH  - Interleukin-4/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Spleen/metabolism
MH  - *Transduction, Genetic
MH  - Tumor Cells, Cultured
EDAT- 2002/06/12 10:00
MHDA- 2003/08/13 05:00
CRDT- 2002/06/12 10:00
PHST- 2002/06/12 10:00 [pubmed]
PHST- 2003/08/13 05:00 [medline]
PHST- 2002/06/12 10:00 [entrez]
AID - S0165247802000718 [pii]
AID - 10.1016/s0165-2478(02)00071-8 [doi]
PST - ppublish
SO  - Immunol Lett. 2002 Aug 1;83(1):13-20. doi: 10.1016/s0165-2478(02)00071-8.